- This event has passed.
STAT Digital Event Series: Combating Covid-19 (Part 2)
Join STAT for a three-part digital event series covering the race for new medicines that will impact Covid-19.
The pandemic caused by the novel coronavirus has shut down countries around the world. One of society’s biggest hopes is that treatments or vaccines can be developed.
Join STAT for a three-part digital event series covering the race for new medicines that will impact Covid-19. The audience will be joined by executives from companies leading the way in developing treatments, who will come prepared to answer tough questions. They’ll discuss current findings, clinical trials, and efforts to expedite approvals as we face this global pandemic.
This series will take place on Zoom, an interactive platform where attendees will be able to not only see the discussions live, but also participate by asking questions during the event. Access to the event is free. Access to the Zoom platform is limited to the first 1,000 attendees; any additional attendees will be able to watch the conversation in real-time via a live stream on STAT’s website.
Part 2: Fighting on multiple fronts. April 29 at 1 p.m. EST
Sponsor Introduction: Richard Moscicki, M.D., chief medical officer and executive vice president of Science and Regulatory Advocacy, PhRMA
Mikael Dolsten, M.D., Ph.D., chief scientific officer, Pfizer
Matt Herper, senior writer, medicine, and editorial director of events, STAT
Unless otherwise specifically stated in relation to each and any of the events listed on this page, the MLSC does not host or sponsor these events. The MLSC has no oversight or responsibility for the venue, content or host-organization related to these events. The MLSC has no affiliation with the organizations listing events or with the events, and provides this content and information as a convenience to visitors to the MLSC website.